8-K: CytoSorbents Reports Q1 2026 Results, Faces Regulatory Hurdles

CytoSorbents Corporation announced its first quarter 2026 financial results, showing a slight revenue increase but a wider net loss, while also providing updates on its DrugSorb-ATR regulatory pathway.

Summary

• Revenue for the first quarter of 2026 was $8.9 million, a 2% increase from $8.7 million in the prior year.
• Gross margin decreased to 69% from 71% in Q1 2025.
• Operating loss improved to $3.0 million from $3.9 million in Q1 2025.
• Net loss widened to $5.1 million ($0.08 per share) from $1.5 million ($0.02 per share) in Q1 2025, primarily due to foreign currency fluctuations.
• Adjusted net loss (excluding currency and stock compensation) was $3.4 million ($0.05 per share), an improvement from $3.7 million ($0.06 per share) in Q1 2025.
• Adjusted EBITDA loss was $2.2 million, an improvement from $2.7 million in Q1 2025.
• Total cash, cash equivalents, and restricted cash was approximately $6.4 million, down from $7.8 million at the end of 2025.
• Total cash burn in the quarter, excluding restructuring payments, was approximately $1.1 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously negative sentiment due to the widening net loss, regulatory delays for a key product, and a decrease in cash reserves, despite some operational improvements and modest revenue growth.

Positives

• Revenue increased by 2% year-over-year to $8.9 million.
• Operating loss decreased to $3.0 million from $3.9 million.
• Adjusted net loss per share improved to $0.05 from $0.06.
• Adjusted EBITDA loss improved to $2.2 million from $2.7 million.
• Cost reduction initiatives implemented in Q4 2025 are showing initial benefits with lower operating expenses.
• The company expects to achieve operating cash flow breakeven in the second half of 2026.
• The FDA identified no concerns regarding device safety for DrugSorb-ATR.
• The STAR-T trial results published in the Journal of Thoracic and Cardiovascular Surgery indicate DrugSorb-ATR is safe and reduces severe bleeding events in CABG patients on ticagrelor.

Negatives

• Net loss widened significantly to $5.1 million due to non-cash foreign currency impacts.
• Gross margin declined to 69% from 71%.
• Total cash, cash equivalents, and restricted cash decreased to $6.4 million from $7.8 million.
• Distributor sales were flat due to delayed orders of approximately $500,000 in the Middle East caused by geopolitical instability.
• The FDA upheld the denial of the original DrugSorb-ATR application for Brilinta, requesting additional information.
• The timeline for submitting a new De Novo application for DrugSorb-ATR for Brilinta has been delayed to late 2026 or early 2027.
• The company is facing challenges in the Middle East market due to geopolitical and economic instability.

Risks

• Geopolitical and economic instability in the Middle East and neighboring regions, related to the U.S.-Iran war, has caused delayed distributor orders.
• The FDA has requested additional mechanistic data for the DrugSorb-ATR De Novo submission for Brilinta, potentially delaying the filing.
• The company's ability to finance its operations and meet financial obligations, including covenants under its debt agreement, is a risk.
• The company's ability to successfully obtain U.S. FDA and Health Canada marketing authorization for DrugSorb-ATR is subject to regulatory review.
• The company's ability to complete its strategic workforce and cost reduction plan to achieve operating cash-flow breakeven is a risk.
• The company's reliance on international markets and distributors exposes it to risks associated with geopolitical events and economic instability.

Future Outlook

The company aims to achieve operating cash flow breakeven in the second half of 2026. They are advancing the U.S. opportunity for DrugSorb-ATR, with clearer regulatory direction from the FDA for the ticagrelor application and are evaluating a potential parallel path for DOACs. Management believes current actions are building a stronger company and positioning it for long-term value.

Management Comments

• First quarter sales were $8.9 million, driven by 13% growth in our direct sales territories outside of Germany.
• Our Germany sales team also performed well, achieving sales slightly below last year, but with a smaller and more focused team reflecting new leadership, sales execution, account targeting, productivity, and customer engagement.
• Given the importance of the German market, we plan to selectively expand our commercial team to improve account coverage and drive growth opportunities in both critical care and cardiac surgery.
• Distributor sales were flat year-over-year, as progress across several territories was offset by delayed distributor orders of approximately $500,000 in parts of the Middle East and neighboring regions due to geopolitical and economic instability related to the U.S.-Iran war.
• Though delayed from our timeline, we now have clearer direction and are committed to obtaining the new information and filing a new De Novo submission as soon as possible.
• While we continue to navigate what we believe to be temporary headwinds in the Middle East, we remain focused on executing on our key priorities including: strengthening commercial performance, reducing operating expenses, and progressing toward our goal of achieving operating cash flow breakeven in the second half of this year.
• We believe the actions we are taking today are building a stronger, more resilient company and positioning us to deliver meaningful long-term value for patients, clinicians, and shareholders.

Industry Context

StockSavvy.ai notes that CytoSorbents' focus on blood purification for critical care and cardiac surgery aligns with a growing trend in advanced medical treatments. The company's efforts to gain FDA approval for DrugSorb-ATR for antithrombotic removal are crucial for expanding its U.S. market presence, especially given the significant market size for DOACs and ticagrelor in cardiac surgery.

Comparison to Industry Standards

• The reported revenue of $8.9 million for Q1 2026 shows modest growth, which may be considered below industry growth rates for rapidly expanding medical device companies, but is positive given the company's specific challenges.
• The net loss of $5.1 million, while impacted by non-cash items, indicates continued investment in R&D and regulatory processes, a common characteristic of companies in the clinical-stage medical device sector.
• The company's cash burn of $1.1 million (excluding restructuring) is a key metric for investors to monitor, as it relates to the runway for future operations and regulatory approvals. This burn rate needs to be compared against similar-stage companies in the medical device space, particularly those with complex FDA approval pathways.
• The delay in the DrugSorb-ATR submission timeline is a significant factor. Companies in this sector often face regulatory delays, and the ability to adapt and resubmit is critical for success. The estimated market size of $500 million to $1 billion annually for DrugSorb-ATR in cardiac surgery in the U.S. is substantial, comparable to other high-value niche medical device markets.

Stakeholder Impact

• Shareholders: The widening net loss, regulatory delays, and decrease in cash reserves may negatively impact shareholder value in the short term. However, the long-term potential of DrugSorb-ATR and the goal of breakeven offer potential upside.
• Employees: Cost reduction initiatives and workforce changes may impact employee morale and job security. The company's focus on growth in Germany and advancing regulatory pathways could create future opportunities.
• Customers (Healthcare Providers): The company's products are critical for patient care. Delays in regulatory approvals for new indications could limit access to potentially beneficial treatments.
• Suppliers: The company's financial health and operational efficiency can impact its ability to meet payment obligations to suppliers.

Next Steps

• Selectively expand the commercial team in Germany to improve account coverage and drive growth.
• Submit a separate pre-submission request to the FDA within the next 30 days to review data for the DOAC removal indication.
• Evaluate options to generate additional mechanistic data for the DrugSorb-ATR De Novo submission on an expedited basis.
• Schedule an additional pre-submission meeting with the FDA, if needed, to discuss and align on the approach for generating mechanistic data.
• Complete required work and submit a new De Novo application for DrugSorb-ATR for Brilinta in late 2026 or early 2027.
• Achieve operating cash flow breakeven in the second half of 2026.

Key Dates

Recommendation

The company shows signs of operational improvement and has a strong long-term product pipeline with significant market potential. However, the widening net loss, ongoing regulatory delays for DrugSorb-ATR, and decreasing cash reserves warrant a cautious approach. Investors should hold to see if the company can achieve its breakeven goals and navigate the FDA approval process successfully.

Keywords

CytoSorbents, CTSO, DrugSorb-ATR, FDA, De Novo application, blood purification, septic shock, financial results